BVS
Bioventus Inc. NASDAQ Listed Feb 11, 2021$8.71
+1.99%
vs $8.54
Mkt Cap $600.2M
52w Low $6.14
53.5% of range
52w High $10.94
50d MA $9.61
200d MA $8.19
P/E (TTM)
21.2x
EV/EBITDA
8.7x
P/B
2.5x
Debt/Equity
1.9x
ROE
15.1%
P/FCF
8.4x
RSI (14)
53.00
ATR (14)
$0.38
Beta
0.69
50d MA
$9.61
200d MA
$8.19
Avg Volume
665.6K
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
4721 EMPEROR BOULEVARD, SUITE 100 · DURHAM, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | BMO | 0.22 | 0.24 | +9.1% | 9.10 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% | — |
| Nov 4, 2025 | BMO | 0.21 | 0.15 | -30.2% | 7.55 | -0.7% | -2.3% | +1.4% | -0.4% | +0.5% | +2.8% | — |
| Aug 6, 2025 | BMO | 0.22 | 0.21 | -4.5% | 7.29 | -0.3% | -4.9% | -0.1% | +0.1% | +5.5% | +3.0% | — |
| May 6, 2025 | BMO | 0.06 | 0.08 | +33.3% | 6.20 | +0.5% | +6.3% | +3.2% | -1.8% | +0.9% | -3.0% | — |
| Mar 11, 2025 | BMO | 0.08 | 0.15 | +87.5% | 10.80 | +0.1% | -6.8% | -4.6% | +0.0% | +2.0% | -2.4% | — |
| Nov 5, 2024 | BMO | 0.06 | 0.06 | +0.0% | 11.48 | +4.5% | -1.7% | -0.4% | +5.2% | +5.2% | -4.8% | — |
| Aug 6, 2024 | BMO | 0.07 | 0.19 | +171.4% | 8.09 | +3.3% | -7.8% | +1.9% | -0.1% | -0.4% | +4.5% | — |
| May 7, 2024 | BMO | -0.05 | 0.07 | +240.0% | 5.12 | +5.5% | -1.6% | +8.3% | -1.1% | +5.9% | +4.7% | — |
| Mar 12, 2024 | BMO | 0.06 | 0.07 | +16.7% | 5.60 | +1.8% | -5.5% | -1.9% | +5.0% | +0.7% | -1.6% | — |
| Nov 7, 2023 | BMO | 0.06 | 0.05 | -16.7% | 3.61 | -0.6% | +5.5% | -7.6% | +0.0% | +5.1% | +1.6% | — |
| Aug 8, 2023 | BMO | 0.03 | 0.14 | +366.7% | 3.88 | +6.7% | +5.4% | +11.7% | -1.1% | +4.9% | +4.2% | — |
| May 16, 2023 | BMO | -0.11 | -0.26 | -136.4% | 1.20 | +0.0% | +9.2% | +11.5% | +33.6% | +7.2% | +16.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Barrington Research | Maintains | Outperform → Outperform | — | $9.10 | $8.96 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% |
| Mar 6 | Craig-Hallum | Maintains | Buy → Buy | — | $9.10 | $8.96 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% |
| Mar 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.61 | $9.54 | -0.7% | +2.0% | -2.4% | +3.9% | -1.9% | -0.9% |
| Dec 17 | JP Morgan | Upgrade | Underweight → Neutral | — | $11.15 | $11.40 | +2.2% | +0.0% | -4.8% | -0.8% | +1.4% | -0.2% |
| Nov 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.48 | $12.00 | +4.5% | -1.7% | -0.4% | +5.2% | +5.2% | -4.8% |
| Sep 27 | Craig-Hallum | Maintains | Buy → Buy | — | $11.05 | $11.52 | +4.3% | +5.3% | +2.7% | -1.3% | -0.1% | -0.9% |
| Aug 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.56 | $7.57 | +0.1% | +4.5% | +1.3% | +3.5% | +4.8% | -7.8% |
| Aug 7 | Craig-Hallum | Maintains | Buy → Buy | — | $8.09 | $8.36 | +3.3% | -7.8% | +1.9% | -0.1% | -0.4% | +4.5% |
| May 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.12 | $5.40 | +5.5% | -1.6% | +8.3% | -1.1% | +5.9% | +4.7% |
| Mar 13 | Craig-Hallum | Maintains | Buy → Buy | — | $5.60 | $5.70 | +1.8% | -5.5% | -1.9% | +5.0% | +0.7% | -1.6% |
| Dec 7 | Canaccord Genuity | Upgrade | Hold → Buy | — | $4.52 | $4.80 | +6.2% | +13.1% | -1.4% | -1.8% | -2.0% | -1.0% |
| Apr 3 | Craig-Hallum | Maintains | Hold → Hold | — | $1.07 | $1.09 | +1.9% | +5.6% | -2.7% | +12.7% | +5.6% | -11.5% |
| Nov 30 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.88 | $1.86 | -1.1% | +3.7% | +11.3% | -1.8% | +5.6% | -2.2% |
| Nov 22 | Craig-Hallum | Downgrade | Buy → Hold | — | $1.88 | $1.82 | -3.2% | -3.7% | +21.0% | +11.9% | -20.4% | -3.6% |
| Nov 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.58 | $2.68 | +3.9% | +25.6% | +2.5% | -5.1% | +4.1% | -9.5% |
| Nov 9 | Canaccord Genuity | Downgrade | Buy → Hold | — | $3.00 | $2.90 | -3.3% | -14.0% | +25.6% | +2.5% | -5.1% | +4.1% |
| Nov 9 | JP Morgan | Downgrade | Overweight → Underweight | — | $3.00 | $2.90 | -3.3% | -14.0% | +25.6% | +2.5% | -5.1% | +4.1% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.95 | $6.83 | -1.7% | -3.5% | -3.7% | -0.3% | -6.4% | +11.1% |
| Sep 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.62 | $7.53 | -1.2% | -2.0% | +5.6% | +2.8% | +4.2% | -3.0% |
| Aug 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.42 | $8.45 | +0.4% | +7.8% | -2.5% | +1.7% | -3.3% | -2.6% |
| May 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.49 | $7.47 | -0.3% | +7.5% | +7.0% | -0.8% | +6.6% | -4.3% |
| Mar 21 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.08 | $13.96 | -0.9% | -2.5% | +0.5% | -6.4% | +0.9% | -0.1% |
| Mar 15 | Craig-Hallum | Maintains | Buy → Buy | — | $12.66 | $13.68 | +8.1% | +6.2% | +2.3% | +2.2% | +0.1% | -2.5% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.03 | $14.18 | +1.1% | -0.4% | -9.4% | +6.2% | +2.3% | +2.2% |
| Jul 1 | Goldman Sachs | Downgrade | Buy → Neutral | — | $17.60 | $16.75 | -4.8% | -2.2% | -4.1% | +0.4% | -3.1% | +1.1% |
| Apr 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.82 | $14.99 | +1.1% | -0.3% | +3.0% | -3.2% | -3.0% | -1.5% |
| Mar 8 | Goldman Sachs | Maintains | Buy → Buy | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | JP Morgan | Maintains | Overweight → Overweight | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
No insider trades available.
8-K
Bioventus Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the summary contains only technical metadata about SEC filing structure rather than actual business information about Bioventus Inc.
Jun 4
8-K · 7.01
! Medium
Bioventus Inc. -- 8-K 7.01: Regulation FD Disclosure
Bioventus' Exogen device reclassification from FDA Class III to Class II reduces regulatory burden and enables CMS to update Medicare reimbursement, potentially improving market access and revenue predictability.
May 21
8-K · 2.02
!! High
Bioventus Inc. -- 8-K 2.02: Earnings Results
Bioventus Inc. released earnings results that investors can review in the attached press release for insight into the company's operational performance and financial condition.
May 6
8-K
Bioventus Inc. -- 8-K Filing
Bioventus reported strong Q4 2025 results with above-market growth and margin improvements, while providing 2026 guidance after strengthening its portfolio and balance sheet.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | 13,021,324 | $119M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,714,707 | $16M | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 973,004 | $9M | New | Mar 2026 |
| 4 | Essex Investment Management Co Llc | 603,258 | $6M | Added | Mar 2026 |
| 5 | Morgan Stanley | 604,516 | $4M | Added | Dec 2025 |
| 6 | Renaissance Technologies Llc | 489,460 | $4M | Reduced | Mar 2026 |
| 7 | Fmr Llc | 396,233 | $4M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 362,823 | $3M | Added | Mar 2026 |
| 9 | Tocqueville Asset Management L.p. | 345,000 | $3M | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 340,038 | $3M | Reduced | Mar 2026 |
| 11 | Acadian Asset Management Llc | 333,115 | $3M | Added | Mar 2026 |
| 12 | D.e. Shaw & Co | 310,610 | $3M | Reduced | Mar 2026 |
| 13 | Sei Investments Co | 289,648 | $3M | Added | Mar 2026 |
| 14 | Knights Of Columbus Asset Advisors Llc | 288,738 | $3M | Reduced | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 279,167 | $3M | Reduced | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 259,060 | $2M | Reduced | Mar 2026 |
| 17 | Jane Street Group, Llc | 269,252 | $2M | Reduced | Dec 2025 |
| 18 | Meros Investment Management, Lp | 207,720 | $2M | Reduced | Mar 2026 |
| 19 | Hrt Financial Lp | 203,645 | $2M | Added | Mar 2026 |
| 20 | Anderson Financial Strategies, Llc | 172,900 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$600.2M
Enterprise Value
$922.1M
P/E (TTM)
21.24x
Forward P/E
11.66x
PEG Ratio
-0.13x
P/B
2.54x
P/S
1.04x
P/FCF
8.41x
EV/EBITDA
8.74x
Shares Out
68.9M
Financials (TTM)
Revenue
$576.3M
Net Income
$28.5M
EBITDA
$105.6M
Free Cash Flow
$71.4M
Op Cash Flow
$74.0M
EPS Basic
$0.43
EPS Diluted
$0.41
EPS Forward
$0.75
Gross Margin
68.7%
Op Margin
10.0%
Net Margin
4.9%
Balance Sheet
Total Assets
$650.5M
Total Liab.
$416.3M
Total Equity
$228.4M
Cash
$35.8M
LT Debt
$357.7M
Book Value/Sh
$3.43
Debt/Equity
1.89x
Current Ratio
1.69
Quick Ratio
1.19
Returns & Growth
ROE
15.1%
ROA
4.4%
ROIC
10.8%
Rev Growth YoY
-0.9%
EPS Growth YoY
+165.4%
Price Returns
2W
-19.8%
1M
-13.8%
3M
-3.1%
6M
+12.1%
12M
+31.3%
Technicals
52W High
$10.94
52W Low
$6.14
50d MA
$9.61
200d MA
$8.19
RSI (14)
53.00
ATR (14)
$0.38
Beta
0.69
Avg Volume
666K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
Mar 26, 2004
Analyst Price Targets
Consensus
$13.00
High
$13.00
Low
$13.00
Median
$13.00
Data updated apr 24, 2026 11:17pm
· Source: financialmodelingprep.com